Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol
Abstract Background There is now a renewed interest in cancer vaccines. Patients responding to immune checkpoint blockade usually bear tumors that are heavily infiltrated by T cells and express a high load of neoantigens, indicating that the immune system is involved in the therapeutic effect of the...
Main Authors: | Sheeba K. Thomas, Soung-chul Cha, D. Lynne Smith, Kun Hwa Kim, Sapna R. Parshottam, Sheetal Rao, Michael Popescu, Vincent Y. Lee, Sattva S. Neelapu, Larry W. Kwak |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4094-2 |
Similar Items
-
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial
by: Szymon J. Szymura, et al.
Published: (2024-08-01) -
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.
by: Alejandro eLopez-Requena, et al.
Published: (2012-11-01) -
Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.
by: Ana María eHernández, et al.
Published: (2012-11-01) -
Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma
by: A. N. Meleshko, et al.
Published: (2017-06-01) -
The 1926 novel, “One, no one, one hundred thousand”, metaphorizes the potential danger when the immune system is exposed to a repetitive antigen stimulation
by: Francesca Ferrazzo, et al.
Published: (2023-09-01)